Significance of aspirin and clopidogrel resistance in patients undergoing percutaneous coronary interventions

Current Vascular Pharmacology

Volumn 5, Issue 2, 2007, Pages 135-140

  Pregowski, Jerzy ^a   Witkowski, Adam ^a   Sitkiewicz, Dariusz ^a  

^a INSTITUTE OF CARDIOLOGY   (Poland)

Author keywords

Aspirin and clopidogrel resistance; Percutaneous coronary interventions

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CLOPIDOGREL; ENZYME; IBUPROFEN; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; TICLOPIDINE;

ACUTE HEART INFARCTION; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG MEGADOSE; ENTERIC COATED TABLET; GENETIC POLYMORPHISM; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; ST SEGMENT ELEVATION; STABLE ANGINA PECTORIS; STENT THROMBOSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS; ANIMAL; BLOOD CLOTTING PARAMETERS; DRUG EFFECT; DRUG INTERACTION; DRUG RESISTANCE; THROMBOCYTE; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; ASPIRIN; BLOOD PLATELETS; DRUG INTERACTIONS; DRUG RESISTANCE; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; TICLOPIDINE;

EID: 34247890094     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016107780368262     Document Type: Review

References (76)

1. Silber S, Albertsson P, Aviles F, Camici P, Colombo A, Hamm C, et al. Guidlines for Percutaneous Coronary Interventions.The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26: 804-47.
2. Roth GJ, Majerus PW. The mechanisms of the effect of aspirin on human platelets. J Clin Invest 1975; 56: 624-32.
3. Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA 1975; 72: 3073-76.
4. Roth GJ, Calverley DC. Aspirin, platelets and thrombosis: theory and practice. Blood 1994; 83: 885-98.
5. Burch JW, Standford N, Majerus PW. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 1978; 61: 314-319.
6. Geiger J, Brich J, Honig-Liedl P, Eigenthaler M, Schanzenbacher P, Herbert JM, et al. Specific impairment of human platelet P2Yac ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol 1999; 19: 2007-2011.
7. Savi F, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000; 84: 891-896.
8. Savi P, Herbert JM, Pflieger AM, Dol F, Delebassee D, Combalbert J, et al. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol 1992; 44: 527-532.
9. Savi P, Combalbert J, Gaich C, Rouchon MC, Maffrand JP, Berger Y, et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost 1994; 72: 313-317.
10. Hermann A, Rauch BH, Braun M, Schror K, Weber AA. Platelet CD40 ligand (CD40L) - subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 2001; 12: 74-82.
11. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
12. Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M, et al. Platelet active drugs: the relationships among dose, effectiveness, and side effects. Chest 2001; 126: 234S-264S.
13. Michelson AD, Cattaneo M, Eikelboom JW, Gurbel P, Kottke-Marchant K, Kunicki TJ, et al. Aspirin resistance: position paper of Working Group on Aspirin Resistance. J Thromb Haemost 2005; 3: 1309-1311.
14. Cattaneo M. Aspirin and clopidogrel: Efficacy, safety and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004; 24: 1980-1987.
15. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
16. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, et al. Credo investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-20.
17. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006; 367: 606-17.
18. Gurbel PA, Tanny US. Drug Insight: clopidogrel nonresponsiveness. Nature Clinical Practice 2006; 3: 387-395.
19. Matetzky S, Shenkman B, Guetta V, Schechter M, Bienart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175.
20. Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, et al. Platelet Reactivity in Patients and Recurrent Events Post-Stenting Results of the PREPARE POST-STENTING Study. J Am Call Cardiol 2005; 46: 1820-6.
21. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis. Results of the CREST Study. J Am Coll Cardiol 2005; 46: 1827-32.
22. Calif RM, DeLong ER, Ostbye T, Muhlbaier LH, Chen A, LaPointe NA, et al. Underuse of aspirin in a referral population with documented coronary artery disease. Am J Cardiol 2002; 89: 653-61.
23. Cotter G, Shemesh E, Zehavi M, Dinur I, Rudnick A, Milo O, et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? Am Heart J 2004; 147: 293-300.
24. Bhatt DL. Aspirin Resistance: More Than Just a Laboratory Curiosity J Am Coll Cardiol 43, 2004: 1127-9
25. Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, et al. Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation A New Drug-Drug Interaction. Circulation 2003; 107: 32-37.
26. Harrison P, Segal H, Balsbery K, Furtado C, Silver L, Rothwell PM. Screening for aspirin responsiveness after transient ischemic attack and stroke. Comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 2005; 36: 1001-05.
27. Bliden KP, Tantry US, Gesheff T. Inconsistency in the prevalence of platelet aspirin resistance as measured by various point-of-service assays in stable cardiovascular patients treated with 81, 162 and 325 mg aspirin. Eur Heart J 2006; 27 (Abstract Suppl.): 864.
28. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 Individuals. J Am Coll Cardiol 2005; 45: 246-51.
29. Mehta J, Mehta P, Burger C, Pepine CJ. Platelet aggregation studies in coronary artery disease. Effect of aspirin. Atherosclerosis 1978; 31: 169-75.
30. Buchanan MR, Brister SJ. Individual variation in the effect of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol 1995; 11: 221-27.
31. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke or cardiovascular death in patients at high risk for cardiovascular event. Circulation 2002; 105: 1650-55.
32. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. Prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961-5.
33. Mobley JE, Bresee SJ, Wortham DC, Craft RM, Snider CC, Carrol RC. Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization Am J Cardiol 2004; 93: 456-458.
34. Calif RM, Abdelmeguid AE, Kuntz RE, Popma JJ, Davidson CJ, Cohen EA, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998; 31: 241-51.
35. Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US. Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets: Results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) Study. Circulation 2005; 111: 1153-1159.
36. Chen WH, Lee PY, Ng W, Tse HF, Lau CP. Aspirin Resistance Is Associated With a High Incidence of Myonecrosis After Non-Urgent Percutaneous Coronary Intervention Despite Clopidogrel Pretreatment. J Am Coll Cardiol 2004; 43: 1122-6.
37. Lev EI, Patel RT, Maresh KJ, Guthikonda S, Granada J, DeLao T, et al. Aspirin and Clopidogrel Drug Response in Patients Undergoing Percutaneous Coronary Intervention The Role of Dual Drug Resistance J Am Coll Cardiol 2006; 47: 27-33.
38. Foussas SG, Patsourakos N, Zairis M. Platelet response to combined aspirin and clopidogrel drug therapy and 1-year mortality after elective coronary stenting. Eur Heart J 2006; 27 (Abstract Suppl): 155.
39. Zairis M, Tsirimpsis V, Perdiou A. Aspirin resistance and long term mortality in patients with non-ST elevation acute coronary syndromes. Eur Heart J 2006; 27 (Abstract Suppl): 864.
40. Cutlip D, Baim DS, Ho KK, Popma JJ, Lansky AJ, Cohen DJ, et al. Stent Thrombosis in the Modern Era A Pooled Analysis of Multicenter Coronary Stent Clinical Trials. Circulation 2001; 103: 1967-1971.
41. Orford JL, Lennon R, Melby S, Fasseas P, Bell MR, Rihaal CS, et al. Frequency and Correlates of Coronary Stent Thrombosis in the Modem Era Analysis of a Single Center Registry. J Am Coll Cardiol 2002; 40: 1567-72.
42. Alfonso F, Suarez A, Angiolillo DJ, Sabate M, Escaned J, Moreno R, et al. Findings of intravascular ultrasound during acute stent thrombosis. Heart 2004; 90: 1455-9.
43. Barragan P, Bouvier JL, Roquebert PO, Macaluso G, Commeau P, Comet B, et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation Catheter Cardiovasc Interv 2003; 59: 295-302.
44. Muller I, Besta F, Schulz C, Massberg S, Schonig, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003; 89: 783-7.
45. Wenaweser P, Dörffler-Melly J, Imboden K, Windecker S, Togni M, Meier B, et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 2005; 45: 1748-52.
46. Ajzenberg N, Aubry P, Huisse MG, Cachier A, El Amara W, Feldman LJ, et al. Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis. A case-control study. J Am Coll Cardiol 2005; 45: 1753-56.
47. Lim E, Cornelissen J, Routledge T, Kirtland S, Sharples L, Sheridan K, et al. Clopidogrel did not inhibit platelet function early after coronary bypass surgery: A prospective randomized trial. J Thorac Cardiovasc Surg 128: 432-435.
48. Ferroni P, Basili S, Falco A, Davi G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2004; 2:1282-1291.
49. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Jimenez-Quevedo P, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005; 54: 2430-2435.
50. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Barrera Ramirez C, Sabate M, Fernandez C, et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? J. Invasive Cardiol 2004; 16: 169-174.
51. Tamminen M, Lassila R., Westerbacka J, Vehkavaara S, Yki-Jarvinen H. Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects. Int J Obes Relat Metab Disord 2003; 27: 907-11.
52. O'Donnell CJ, Larson MG, Feng D, Sutherland PA, Lindpainter K, Myers RH, et al. Genetic and environmental contributions to platelet aggregation: the Framingham heart study. Circulation 2001; 26; 103: 3051-6.
53. Halushka M, Walker LP, Haushaka PV. Genetic variation in cyclooxygenase 1. Effects on response to aspirin. Clin Pharmacol Ther 2003; 73: 122-30.
54. Cipollone F, Toniato E, Martinotti S. Identifications of New Elements of Plaque Stability (INES) Study Group. A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction or stroke. JAMA 2004; 29: 2221-28.
55. Cambria-Kiely JA, Gandhi PJ. Aspirine resistance and genetic polymorphisms. J Thromb Thrombolysis 2002; 14: 51-58.
56. Cooke GE, Liu-Stratton Y, Ferketich AK, Moeschberger ML, Frid DJ, Magorien RD, et al. Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination J Am Col Cardiol 2006; 47: 541-6.
57. Fontana P, Gaussem P, Aiach M, Fiessinger JN, Emmerich J, Reny JL. P2Y12 H2 Haplotype Is Associated With Peripheral Arterial Disease A Case-Control Study. Circulation 2003; 108: 2971-2973.
58. Beer JH, Pederiva S, Pontiggia L. Genetics of platelet receptor single-nucleotide polimorphisms: clinical implications in thrombosis. Ann Med 2000; 32: 10-14.
59. Wiliams FM. Clinical significance of esterases in man. Clin Pharmacokinet 1985; 10: 392-403.
60. Anand BS, Sanduja SK, Lichtenberger LM. Effect of omeprazole on the bioavailability of aspirin: a randomized controlled study on healthy volunteers. Gastroenterology 1999;116: A371.
61. Inarrea P, Esteva F, Cornudella R, Lanas A. Omeprazole does not interfere with the antiplatelet effect of low dose aspirin in man. Scand J Gastroenterol 2000; 35: 242-246.
62. Livio M, Del Maschio A, Cerletti C, de Gaetano G. Indomethacin prevents the long-lasting inhibitory effect of aspirin on human platelet cyclo-oxygenase activity. Prostaglandins 1982; 23: 787-96.
63. Rao GH, Johnson GG, Reddy KR, White JG. Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin. Arteriosclerosis 1983; 3: 383-8.
64. Kurth T, Glynn RJ, Walker A, Chan KA, Buring XE, Hennekens CH, et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal anti-inflammatory drugs. Circulation 2003; 108: 1191-5.
65. Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, et al. The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. J Am Coll Cardiol 2004; 43: 985-90.
66. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809-17.
67. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin Lancet 2003; 1361: 573-574.
68. Curtis JP, Krumholz HM. The Case for an Adverse Interaction Between Aspirin and Non-Steroidal Anti-Inflammatory Drugs Is it Time to Believe the Hype? J Am Coll Cardiol 2004; 43: 991-993.
69. Maree AO, Curtin RJ, Dooley M, Conroy RM, Crean P, Cox D, et al. Platelet Response to Low-Dose Enteric-Coated Aspirin in Patients With Stable Cardiovascular Disease. J Am Coll Cardiol 2005; 47: 1258-63.
70. Cox D, Maree AO, Dooley M. Lower bioavailability and weight dependence of enteric-coated aspirin preparations (abstr). Arterioscler Thromb Vasc Biol 2004; 24: e53.
71. Mitsios JV, Papathanasiou AI, Rodis FI,Elisaf M, Goudevenos JA, Tselepis AD. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 2004; 109: 1335-1338.
72. Müller I, Bests F, Schulz C, Li Z, Massberg S, Gawaz M. Effects of Statins on Platelet Inhibition by a High Loading Dose of Clopidogrel. Circulation 2003; 108: 2195-2197.
73. Saw J, Steinhubl SR, Berger PB, Kereiakes DJ, Serebruany VL, Brennan D, et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003; 108: 921-924.
74. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention - Summary Article. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention) Circulation 2005; 113: 156-175.
75. Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, et al. Randomized Comparison of Prasugrel (CS-747, LY640315), a Novel Thienopyridine P2Y12 Antagonist, With Clopidogrel in Percutaneous Coronary Intervention Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 Trial. Circulation 2005; 111: 3366-3373.
76. Serebruany VL, Midei MG, Meilman H, Malinin AI, Lowry DR. Platelet inhibition with prāsugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study. Postgrad Med J 2006; 82: 404-10.